| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
STING (stimulator of interferon genes). SN-008 is a structural analog of the STING antagonist SN-011 but exhibits significantly lower activity. It is used as a negative control to validate the specificity of STING-targeting effects observed with active compounds such as SN-011. The compound does not significantly inhibit STING signaling, making it a suitable control for distinguishing specific from non-specific effects.
|
|---|---|
| ln Vitro |
SN-008 is a less active analog of SN-011, which is a STING antagonist. As a negative control compound, it does not exhibit significant STING antagonistic activity. Its primary use is in control experiments to confirm that the effects observed with SN-011 are specifically due to STING antagonism rather than non-specific off-target effects.
|
| ln Vivo |
In vivo, SN-008 is used as a negative control to validate the specificity of STING-targeting effects observed with active compounds. By administering SN-008 alongside SN-011 in animal studies, researchers can confirm that the therapeutic effects or biological responses observed are specifically due to STING antagonism and not non-specific effects of the compound scaffold.
|
| Enzyme Assay |
In vitro binding and functional assays for SN-008 are performed to confirm its lack of activity as a STING antagonist. These assays typically involve treating STING-expressing cells with SN-008 and measuring downstream signaling (such as IFN-β expression or IRF3 activation) in comparison to the active compound SN-011. The absence of significant inhibition confirms that SN-008 is a suitable negative control.
|
| Cell Assay |
Cellular assays for SN-008 are performed alongside assays for the active compound SN-011. STING-expressing cells are treated with SN-008 (at concentrations comparable to SN-011) and the lack of inhibition of STING-mediated signaling is confirmed. Readouts include IFN-β expression, IRF3 phosphorylation, and other STING pathway activation markers. The compound's lack of activity validates the specificity of results obtained with SN-011.
|
| Animal Protocol |
In vivo studies with SN-008 are performed as control experiments alongside studies with the active compound SN-011. The compound is administered via the same route and at comparable doses to confirm that any observed in vivo effects are specifically due to STING antagonism and not non-specific effects of the compound scaffold.
|
| ADME/Pharmacokinetics |
SN-008 has a molecular formula of C25H19FN2O3S and a molecular weight of 446.49. It is supplied with a purity of ≥96%. The compound is soluble in DMSO. It should be stored under recommended conditions. It is for research use only and is not intended for human therapeutic use.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for SN-008. As a negative control compound used in research, it is not intended for therapeutic applications. Standard safety precautions should be observed when handling this research compound.
|
| References | |
| Additional Infomation |
SN-008 (CAS#: 2249106-01-0) is a less active analog of SN-011, which is a STING antagonist. It has a molecular formula of C25H19FN2O3S and a molecular weight of 446.49. SN-008 is used as a negative control (NC) in research studies investigating STING signaling pathways. It is a research tool and is not approved for clinical use.
|
| Molecular Formula |
C25H19FN2O3S
|
|---|---|
| Molecular Weight |
446.493368387222
|
| Exact Mass |
446.11
|
| CAS # |
2249106-01-0
|
| PubChem CID |
138005723
|
| Appearance |
White to off-white solid powder
|
| LogP |
5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
32
|
| Complexity |
703
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C=CC(=CC=1)F)(NC1C=CC=C(C=1)NC(C1C=CC(=CC=1)C1C=CC=CC=1)=O)(=O)=O
|
| InChi Key |
GFQARWFKDMDSAS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H19FN2O3S/c26-21-13-15-24(16-14-21)32(30,31)28-23-8-4-7-22(17-23)27-25(29)20-11-9-19(10-12-20)18-5-2-1-3-6-18/h1-17,28H,(H,27,29)
|
| Chemical Name |
N-[3-[(4-fluorophenyl)sulfonylamino]phenyl]-4-phenylbenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (223.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.60 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2397 mL | 11.1985 mL | 22.3969 mL | |
| 5 mM | 0.4479 mL | 2.2397 mL | 4.4794 mL | |
| 10 mM | 0.2240 mL | 1.1198 mL | 2.2397 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
